Non-squamous NSCLC Clinical Trial
Official title:
Pembrolizumab Plus Bevacizumab and Chemotherapy as First-Line Treatment for Advanced or Metastatic Non-Squamous NSCLC Patients With EGFR Exon 20 Insertion Mutation: An Open-Label, Single-Arm, Phase II Trial
This study is designed to evaluate the efficacy and safety of Pembrolizumab in combination with Bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04447118 -
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
|
Phase 3 | |
| Active, not recruiting |
NCT04413201 -
AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC
|
Phase 4 | |
| Completed |
NCT05261438 -
Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
|
||
| Recruiting |
NCT03755869 -
Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）
|
Phase 4 | |
| Withdrawn |
NCT04466917 -
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT05782426 -
Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC
|
Phase 2 | |
| Terminated |
NCT02454842 -
Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients
|
Phase 2 | |
| Not yet recruiting |
NCT06206850 -
Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib
|
Phase 2 |